Tandem Diabetes (TNDM) Tops Q4 EPS by 22c ; Offers Guidance

Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.01, $0.22 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $282.65 million versus the consensus estimate of $251.3 million.

GUIDANCE:

Tandem Diabetes sees FY2025 revenue of $0.99-1.01 billion, versus the consensus of $1.01 billion.

Tandem Diabetes sees Q1 2025 revenue of $219-224 million, versus the consensus of $220.7 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• JPMorgan Downgrades KFin Technologies Ltd (KFINTECH:IN) to Neutral
• HDFC Asset Management Co Ltd (HDFCAMC:IN) PT Raised to INR3,250 at JPMorgan